الفهرس 
List of ContentOnly 14 pages are availabe for public view
 |  | from | 128 |  |  |
| | | from | 128 | | |
Abstract
The first observation of probable correlation between DAAS and HCC was first reported by (Conti et al., 2016) who showed unexpected higher rate of HCC recurrence after local ablation of HCC in patients who received DAAS for HCV treatment. Our study aimed to determine clinical, laboratory and radiological characteristics of HCC developing in patients after treatment of chronic HCV with DAAS. In our study, we found that patients who developed HCC after DAAS were characterized by: 1- Lower prevalence of obesity than in patients who developed de novo HCC without prior DAAS treatment. 2- Higher prevalence of renal impairment in patients who developed HCC after receiving DAAS than patients who didn’t receive DAAS. 3- Patients who developed HCC after receiving DAAS presented by symptoms as dyspepsia and fever more commonly than patients who develop de novo HCC. 4- Patients in the case group had higher serum ALT, AFP and albumin levels than patients in control group, while patients in the control group had higher levels of serum total bilirubin and prolonged PT. Also, 82% of patients in the case group were CHILD PUGH CLASS A, in contrast with patients in control group who were CHILD PUGH CLASS A in only 52%which may be due to preserved liver functions in patients who received DAAS with successful viral clearance. 5- The diffuse infiltrating pattern of HCC with vascular invasions and enlarged metastatic porta- hepatis lymph nodes were more common in patients who had before received treatment with DAAS. 6- Serum AFP was significantly higher in patients who developed HCC after treatment with DAAS than those with de novo HCC. Metastasis was more common in patients who developed HCC after DAAS than in patients who developed de novo HCC, due to aggressive biological behavior of the tumor.